Navid Hakimian
Pulmonary Disease · Los Angeles, CANPI 1619979606
Payments from drug & device makers
Across 8 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$86
- Edwards Lifesciences$57
- Intuitive Surgical$44
- Sanofi$34
- Genentech USA, Inc.$14
What the payments were for
- Food & beverage$235100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 4 | $86 |
| Edwards Lifesciences | 1 | $57 |
| Intuitive Surgical | 1 | $44 |
| Sanofi | 1 | $34 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$235 in reported general payments places this provider in the 25th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 168 | $201,791 |
| Dupixent SyringeDupilumab | 34 | $118,263 |
| Pirfenidone | 17 | $96,193 |
| OzempicSemaglutide | 80 | $89,874 |
| EliquisApixaban | 64 | $56,134 |
| JanuviaSitagliptin Phosphate | 30 | $42,913 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $39,181 |
| MounjaroTirzepatide | 34 | $37,597 |
| FarxigaDapagliflozin Propanediol | 25 | $24,742 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $20,275 |
| JardianceEmpagliflozin | 11 | $18,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $17,752 |
| Wixela InhubFluticasone Propion/Salmeterol | 45 | $14,973 |
| Spiriva RespimatTiotropium Bromide | 16 | $14,972 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 319 | $12,678 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.